Nuvation Bio Inc. (NUVB)
Nuvation Bio develops oral cancer drugs, led by IBTROZI for a form of advanced lung cancer, and is based in New York. It last closed at $3.90 on Nov 17, up 1.17% on the day. The average 12-month price target from 3 analysts is $13.00 (+232.9% from the last close), with a high of $17.00 and a low of $10.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 4 dark pool prints totaling $1.5M, the largest $1.0M.
Key Stats
Last 12 monthsNot reported for this period.
From NUVB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on NUVB in the past 90 days. The average target is $13.00, with a high of $17.00 and a low of $10.00, compared with the last close of $3.90.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 5 | RBC Capital | Target lowered | Buy | $19 → $17 |
| Sep 30 | Citigroup | Initiated | Buy | $12 |
| Sep 16 | Citizens | Reiterated | Buy | $10 |
| Aug 18 | JP Morgan | Initiated | Buy | $13 |
| Jul 27 | HC Wainwright & Co. | Maintained | Buy | $21 |
Technical Analysis
The stock is 13% below its 20 day and 28% below its 50 day average. It is 36% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the Pivot at $3.89, and the nearest resistance the Pivot R1 at $3.99.
| RSI (14) | 31.68 | Weak, oversold below 30 | Neutral |
| MACD | -0.30 | Below its signal line | Bearish |
| Stochastic | 6.5 | Near the bottom of its range | Oversold |
| ADX (14) | 38.5 | Trending down | |
| Williams %R | -89.9 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -137.0 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −16.9% | Change over 10 sessions | Bearish |
| ATR (14) | $0.25 | Typical daily range, 6.5% of price |
| RSI (14) | 34.03 | Weak, oversold below 30 | Neutral |
| MACD | -0.37 | Below its signal line | Bearish |
| Stochastic | 3.0 | Near the bottom of its range | Oversold |
| ADX (14) | 21.2 | Weak trend | |
| Williams %R | -97.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -136.6 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −35.7% | Change over 10 sessions | Bearish |
| ATR (14) | $0.68 | Typical daily range, 17.3% of price |
What happened before
See how NUVB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NUVB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in NUVB in the last 90 days.
Dark Pool
30DNUVB Institutional Ownership
Full report →- ▲138 buying vs 95 selling
- ▲Held by funds +5.3 pts
- ▲Funds holding +14
- ●Superinvestors: 2 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 261 | 247 | +5.7% |
| In funds' top 10 | 6 | 5 | +20.0% |
| Held by funds | 72.6% | 67.3% | +5.3 pts |
| New / increased | 38 / 100 | 42 / 111 | −9.8% |
| Reduced / sold out | 72 / 23 | 51 / 25 | +25.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NUVB is in one of them and how their past NUVB trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NUVB in an article yet. Here's the latest on the wider market.
About Nuvation Bio
Nuvation Bio is an oncology company that develops cancer medicines in the form of small molecules, which are chemically designed drugs taken by mouth. Its main approved product, IBTROZI, treats adults with a form of advanced lung cancer that has a specific genetic change. Its other lead program, safusidenib, is being tested for a type of brain tumor called astrocytoma. The company is based in New York, and its partners sell the lung cancer treatment in Japan and China.
- Headquarters
- New York, NY


